[1] Valadi H, Ekström K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.[2] 刘儒涛,王世伟,刘晶.细胞间信息交流的新载体——外泌体[J].生物化学与生物物理进展,2013,40(8):719-727.[3] Tickner JA, Richard DJ, O'Byrne KJ. EV, Microvesicles/MicroRNAs and Stem Cells in Cancer. Adv Exp Med Biol. 2018;1056:123-135.[4] DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-271.[5] 陈万青,李贺,孙可欣,等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2018,40(1):5-13.[6] Mirzaei H, Fathullahzadeh S, Khanmohammadi R, et al. State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. J Cell Physiol. 2018;233(2):888-900.[7] Nawaz M. Extracellular vesicle-mediated transport of non-coding RNAs between stem cells and cancer cells: implications in tumor progression and therapeutic resistance. Stem Cell Investig. 2017; 4:83.[8] Barrera-Ramirez J, Lavoie JR, Maganti HB, et al. Micro-RNA Profiling of Exosomes from Marrow-Derived Mesenchymal Stromal Cells in Patients with Acute Myeloid Leukemia: Implications in Leukemogenesis. Stem Cell Rev. 2017;13(6):817-825.[9] Bayraktar R, Van Roosbroeck K, Calin GA. Cell-to-cell communication: microRNAs as hormones. Mol Oncol. 2017;11(12): 1673-1686.[10] Ohno S, Kuroda M. Exosome-Mediated Targeted Delivery of miRNAs. Methods Mol Biol. 2016;1448:261-270.[11] Caivano A, Laurenzana I, De Luca L, et al. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumour Biol. 2015;36(12):9739-9752.[12] Tadokoro H, Umezu T, Ohyashiki K, et al. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013;288(48):34343-34351.[13] Umezu T, Ohyashiki K, Kuroda M, et al. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene. 2013;32(22): 2747-2755.[14] Paggetti J, Haderk F, Seiffert M, et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 2015;126(9): 1106-1117.[15] Taverna S, Flugy A, Saieva L, et al. Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer. 2012;130(9):2033-2043.[16] Taverna S, Amodeo V, Saieva L, et al. Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells. Mol Cancer. 2014; 13:169.[17] El-Saghir J, Nassar F, Tawil N, et al. ATL-derived exosomes modulate mesenchymal stem cells: potential role in leukemia progression. Retrovirology. 2016;13(1):73.[18] Bruns H, Böttcher M, Qorraj M, et al. CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D. Leukemia. 2017;31(4):985-988.[19] Habiel DM, Krepostman N, Lilly M, et al. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma. Oncotarget. 2016;7(50): 83514-83529.[20] Viola S, Traer E, Huan J, et al. Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance. Br J Haematol. 2016; 172(6):983-986.[21] Farahani M, Rubbi C, Liu L, et al. CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p. PLoS One. 2015;10(10): e0141429.[22] Ohyashiki K, Umezu T, Katagiri S, et al. Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib. Int J Mol Sci. 2016;17(4):570.[23] 郭敏,李育敏,费嘉.以microRNA-21为靶标反义寡核苷酸对人白血病K562细胞的抑制作用[J].中国病理生理杂志, 2009,25(6):1127-1131.[24] Fraser M, Leung BM, Yan X, et al. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 2003;63(21):7081-7088.[25] Hornick NI, Huan J, Doron B, et al. Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML. Sci Rep. 2015;5:11295.[26] Hornick NI, Doron B, Abdelhamed S, et al. AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci Signal. 2016;9(444):ra88.[27] Barrera-Ramirez J, Lavoie JR, Maganti HB, et al. Micro-RNA Profiling of Exosomes from Marrow-Derived Mesenchymal Stromal Cells in Patients with Acute Myeloid Leukemia: Implications in Leukemogenesis. Stem Cell Rev. 2017;13(6):817-825.[28] Peng D, Wang H, Li L, et al. miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding. Leukemia. 2018;32(5):1180-1188.[29] Asano M, Umezu T, Katagiri S, et al. Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors. Int J Hematol. 2017;105(4):419-422.[30] Yeh YY, Ozer HG, Lehman AM, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood. 2015;125(21): 3297-3305.[31] Taverna S, Giallombardo M, Pucci M, et al. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21. Oncotarget. 2015;6(26): 21918-21933.[32] Lim JH, Song MK, Cho Y, et al. Comparative analysis of microRNA and mRNA expression profiles in cells and exosomes under toluene exposure. Toxicol In Vitro. 2017;41:92-101.[33] Boyiadzis M, Whiteside TL. Information transfer by exosomes: A new frontier in hematologic malignancies. Blood Rev. 2015;29(5): 281-290.[34] Yao Y, Wang C, Wei W, et al. Dendritic cells pulsed with leukemia cell-derived exosomes more efficiently induce antileukemic immunities. PLoS One. 2014;9(3):e91463. [35] 郭芳,常春康,范华骅,等. 环磷酰胺联合树突状细胞分泌的外泌体和Poly Ⅰ∶C的抗肿瘤作用研究[J].中国输血杂志, 2008, 21(10): 759-762.[36] 范震,蔡国龙,严静,等.MicroRNA对脓毒症炎症因子的调控[J].中国急救医学,2010,30(3):271-274.[37] Fu C, Jiang L, Xu X, et al. STAT4 knockout protects LPS-induced lung injury by increasing of MDSC and promoting of macrophage differentiation. Respir Physiol Neurobiol. 2016;223:16-22.[38] 苏强,李浪.PTEN与炎症关系的研究进展[J].重庆医学, 2014,43(4): 494-497.[39] Luyendyk JP, Schabbauer GA, Tencati M, et al. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J Immunol. 2008;180(6):4218-4226.[40] Ufkin ML, Peterson S, Yang X, et al. miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res. 2014;38(3):402-410.[41] Bai H, Zhou L, Wang C, et al. Involvement of miR-125a in resistance to daunorubicin by inhibiting apoptosis in leukemia cell lines. Tumour Biol. 2017;39(4):1010428317695964.[42] Puissegur MP, Eichner R, Quelen C, et al. B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells. Leukemia. 2012;26(10):2224-2232.[43] Due H, Svendsen P, Bødker JS, et al. miR-155 as a Biomarker in B-Cell Malignancies. Biomed Res Int. 2016;2016:9513037.[44] Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243-249.[45] Zhang X, Zeng J, Zhou M, et al. The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer. 2012;11:56.[46] Yan-Fang T, Jian N, Jun L, et al. The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML). BMC Med Genet. 2013;14:74.[47] Akao Y, Iio A, Itoh T, et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther. 2011; 19(2):395-399.[48] 张娟娟,李瑞玮,贺继刚,等. 白血病细胞源外泌体的作用研究进展[J].中国病理生理杂志, 2017, 33(12):2287-2292. |